{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:38Z","timestamp":1790774678894,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.semnephrol.2025.151568","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:23:30Z","timestamp":1741638210000},"page":"151568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Pathology of IgA Nephropathy: How Can It Inform Management?"],"prefix":"10.1016","volume":"44","author":[{"given":"Mark","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2025.151568_bib0001","series-title":"Heptinstall's Pathology of the Kidney","first-page":"591","article-title":"IgA nephropathy and IgA vasculitis (Henoch-Schonlein purpura) nephritis","author":"Haas","year":"2023"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0002","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1","volume":"30","author":"Rizk","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/path.1711770214","article-title":"Spatial arrangement of IgA and C3 as a prognostic indicator of IgA nephropathy","volume":"177","author":"Onetti Muda","year":"1995","journal-title":"J Pathol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0004","first-page":"1002","article-title":"Aberrant O-glycosylation of IgA1 and complement in IgA nephropathy: glomerular immunodeposits of patients with histologically active disease exhibit elevated colocalization of IgA and complement C3","volume":"3","author":"Novak","year":"2023","journal-title":"Glycobiology"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0005","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0006","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0007","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0008","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0009","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0010","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new International Risk-Prediction Tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0011","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ekir.2020.07.036","article-title":"External validation of international risk-prediction models of IgA nephropathy in an Asian-Caucasian cohort","volume":"5","author":"Zhang","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0012","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D'Amico","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40620-015-0227-8","article-title":"Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression","volume":"20","author":"Chaker","year":"2016","journal-title":"J Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0014","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0015","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/ndt\/gfq812","article-title":"Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort","volume":"26","author":"Bellur","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0016","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1681\/ASN.2021081086","article-title":"Galactose-deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors","volume":"33","author":"Zachova","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0017","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactorse-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0018","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.3390\/jcm12237361","article-title":"Colocalization of IgG and IgA heavy chains with kappa and lambda light chains in glomerular deposits of IgA nephropathy patients using high-resolution confocal microscopy and correlation with Oxford MEST-C scores","volume":"12","author":"Rizk","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0019","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/his.14318","article-title":"Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy","volume":"78","author":"Wu","year":"2021","journal-title":"Histopathology."},{"key":"10.1016\/j.semnephrol.2025.151568_bib0020","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.0000000000000290","article-title":"Mesangial C3 deposition, complement-associated variant, and disease progression in IgA nephropathy","volume":"18","author":"Kang","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0021","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40620-022-01363-4","article-title":"Predictive prognostic value of glomerular C3 deposition in IgA nephropathy","volume":"36","author":"Xie","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0022","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0023","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.kint.2017.03.041","article-title":"Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy","volume":"92","author":"Tortajada","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0024","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5414\/CNP66397","article-title":"A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy","volume":"66","author":"Chang","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0026","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.ajkd.2019.03.416","article-title":"Microangiopathic lesions in IgA nephropathy: a cohort study","volume":"74","author":"Cai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0027","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41379-019-0259-z","article-title":"Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis","volume":"32","author":"Chua","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0028","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0029","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2001.27689","article-title":"Predicting progression in IgA nephropathy","volume":"38","author":"Bartosik","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0030","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nehropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0031","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0032","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial","volume":"380","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0033","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2 year results from a randomized phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0034","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomized, double-blind, active controlled clinical trial","volume":"410","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0035","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0036","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0037","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","article-title":"Roberts IS. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"91","author":"Bellur","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0038","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0039","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2025.151568_bib0041","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability, and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929525000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929525000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T14:48:32Z","timestamp":1746542912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929525000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0270929525000051"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151568","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pathology of IgA Nephropathy: How Can It Inform Management?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151568"}}